Modified factor IX preparation
OwnerDouglas E. Bigler, Sourav K. Kundu +2inventors
InventorsDouglas E. Bigler, Sourav K. Kundu, Holger Lind, Stefan Schulte
Life of this patent
Estimating the term…
Abstract
The present invention relates to a modification of the anion exchange chromatography step in a Factor IX purification process. By the modification the presence of the protease, plasma hyaluronan binding protease, is decreased which minimizes the cleavage of Factor IX and enhances the yield of Factor IX in the purification process.
Claims18
A method for increasing Factor IX stability without sacrificing Factor IX yield by separating Factor IX from plasma hyaluronan binding protease, said method comprising:
- a. obtaining a crude Factor IX protein-containing sample;
- b. contacting said sample with an ionic exchange chromatographic medium so that said Factor IX protein binds;
- and
- c. eluting said Factor IX protein from the chromatographic medium with a low ionic strength solution comprising between about 0.35M to 0.4M salt;
- whereby said Factor IX is separated from the plasma hyaluronan binding protease thereby increasing the stability of Factor IX.
A method for increasing the ratio of Factor IX to plasma hyaluronan binding protease, said method comprising:
- a. obtaining a crude Factor IX protein-containing sample;
- b. contacting said sample with an ionic exchange chromatographic medium so that said Factor IX protein binds;
- and
- c. eluting said Factor IX protein from the chromatographic medium with a low ionic strength solution comprising between about 0.35M to 0.4M salt;
- whereby said Factor IX is separated from said protease thereby increasing the ratio of Factor IX to said plasma hyaluronan binding protease.
A method for decreasing the extent of Factor IX degradation, said method comprising:
- a. obtaining a crude Factor IX protein-containing sample;
- b. contacting said sample with an ionic exchange chromatographic medium so that said Factor IX protein binds;
- and
- c. eluting said Factor IX protein from the chromatographic medium with a low ionic strength solution comprising between about 0.35M to 0.4M salt;
- whereby said Factor IX is separated from plasma hyaluronan binding protease thereby decreasing the extent of Factor IX degradation.
Dependencies are inferred from the claim text.